Epstein-Barr virus-positive mucocutaneous ulcer in a patient with ulcerative colitis: a recently described entity to take into account

• Published in: Revista española de enfermedades digestivas Vol. 116; no. 11; p. 645
• Main Authors: Yagüe Parada, Álvaro, Bosch Esteva, Orencio, Calero Barón, Daniel, Blanco Fernández, Andrea, Castellano Megías, Víctor Manuel, Rodríguez Vargas, Sara Aurora
• Format: Journal Article
• Language: English
• Published: Spain 01-01-2024
• ISSN: 1130-0108
• DOI: 10.17235/reed.2024.10168/2023

Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) is a new entity recently included in the classification of B-cell lymphoproliferative disorders associated with Epstein-Barr virus (EBV). It is related to immunosuppression and it usually appears in the oropharynx or the skin, being the colon an uncommon location. We present the case of a 31-year-old man with ulcerative proctitis being treated with azathioprine (AZA) and adalimumab (ADA), who was admitted to the hospital due to suspicion of a moderate-severe flare of ulcerative proctitis. Microbiological stool analyses were negative, with a positive fecal calprotectin test (2700 mg/kg). Rectoscopy showed severe endoscopic activity, taking multiple biopsies. Intravenous steroids were started at a dose of 60 mg/day. He presented a favorable clinical and analytical evolution, being discharged from the hospital. The histological results were received at gastroenterology consultation, being compatible with EBVMCU. AZA and ADA were withdrawn, whereas descending steroid regimen and oral and topical mesalazine were continued, being the clinical response adequate.